JAMES TREACE - 30 Jan 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for James T. Treace
Issuer symbol
TMCI
Transactions as of
30 Jan 2023
Net transactions value
-$883,092
Form type
4
Filing time
30 Jan 2023, 17:35:57 UTC
Previous filing
14 Dec 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale $648,801 -28,214 -2.7% $23.00 1,033,227 30 Jan 2023 Direct F1, F2
transaction TMCI Common Stock Sale $208,412 -8,803 -0.85% $23.68 1,024,424 30 Jan 2023 Direct F1, F3
transaction TMCI Common sotk Sale $25,880 -1,054 -0.1% $24.55 1,023,370 30 Jan 2023 Direct F1, F4
holding TMCI Common Stock 556,183 30 Jan 2023 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.3500 to $23.3400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.3500 to $24.3300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.3600 to $25.0600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.